Patents by Inventor Allan R. Shepard

Allan R. Shepard has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • INHIBITORS OF PROTEIN KINASE C-DELTA FOR THE TREATMENT OF GLAUCOMA
    Publication number: 20080153903
    Abstract: The present invention relates to methods to treat and/or prevent increased intraocular pressure in a subject by administering a protein kinase C-delta (PKC?) inhibitor. In further embodiments, the present invention relates to methods to treat and/or prevent glaucoma by administering a PKC? inhibitor.
    Type: Application
    Filed: December 20, 2007
    Publication date: June 26, 2008
    Applicant: ALCON MANUFACTURING, LTD.
    Inventors: Debra L. FLEENOR, Iok-Hou PANG, Allan R. SHEPARD, Abbot F. CLARK
  • ANTAGONISTS OF CI-M6P/IGF2R FOR PREVENTION AND TREATMENT OF CTGF-MEDIATED OCULAR DISORDERS
    Publication number: 20080057072
    Abstract: Antagonists of cation-independent mannose 6-phosphate/insulin-like growth factor-II receptor are provided for attenuation of CTGF signaling in a method of down-regulation of receptor signaling and downstream decreased signaling of connective tissue growth factor in ocular disorders involving inappropriate CTGF signaling. Ocular disorders involving inappropriate CTGF signaling include ocular hypertension, glaucoma, glaucomatous retinopathy, optic neuropathy, macular degeneration, diabetic retinopathy, choroidal neovascularization, and proliferative vitreoretinopathy, for example. Such disorders are treated by administering antagonists of the present invention.
    Type: Application
    Filed: August 30, 2007
    Publication date: March 6, 2008
    Applicant: ALCON MANUFACTURING, LTD.
    Inventors: Allan R. SHEPARD, Debra L. FLEENOR, Abbot F. CLARK, Najam A. SHARIF
  • ANTAGONISTS OF ENDOTHELIAL DIFFERENTIATION GENE SUBFAMILY 3 (EDG-3, S1P3) RECEPTORS FOR PREVENTION AND TREATMENT OF OCULAR DISORDERS
    Publication number: 20080025973
    Abstract: Antagonists of S1P3 (Edg-3) receptors are provided for attenuation of Smad signaling in a method of down-regulation of receptor signaling and downstream decreased production of connective tissue growth factor in ocular disorders involving CTGF accumulation. Ocular disorders involving inappropriate CTGF accumulation include ocular hypertension, glaucoma, glaucomatous retinopathy, optic neuropathy, macular degeneration, diabetic retinopathy, choroidal neovascularization, proliferative vitreoretinopathy and ocular wound healing, for example. Such disorders are treated by administering antagonists of the present invention.
    Type: Application
    Filed: July 25, 2007
    Publication date: January 31, 2008
    Applicant: ALCON MANUFACTURING, LTD.
    Inventors: Debra L. FLEENOR, Allan R. SHEPARD, Iok-Hou PANG